Antibiotics for community-acquired pneumonia in adult outpatients

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Pakhale, Smita ^a   Mulpuru, Sunita ^b   Verheij, Theo J M ^c   Kochen, Michael M ^d   Rohde, Gernot G U ^e,f   Bjerre, Lise M ^g  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f CAPNETZ STIFTUNG   (Germany)

^g UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CETHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; ERYTHROMYCIN STEARATE; LEVOFLOXACIN; NEMONOXACIN; SOLITHROMYCIN; TELITHROMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; GASTRITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; MORNING DOSAGE; NAUSEA; NEUROLOGIC DISEASE; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADULT; COMMUNITY-ACQUIRED INFECTIONS; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; OUTPATIENTS; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84921988670     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002109.pub4     Document Type: Review

References (157)

1. Anderson G, Esmonde TS, Coles S, Macklin J, Carnegie C. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. Journal of Antimicrobial Chemotherapy 1997;27(Suppl A):117-24.
2. Chien SM, Pichotta P, Siepman N, Chan CK and the Canada-Sweden Clarithromycin-Pneumonia Group. Treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Chest 1993;103:697-701.
3. D'Ignazio J, Camere MA, Lewis DE, Jorgensen D, Breen JD. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrobial Agents and Chemotherapy 2005;49(10):4035-41.
4. Drehobl MA, De Salvo MC, Lewis DE, Breen JD. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 128;4:2230-7.
5. English ML, Fredericks CE, Milanesio NA, Rohowsky N, Xu Z-Q, Jenta TRJ, et al. Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. Antimicrobial Agents and Chemotherapy 2011;56(4):2037-47.
6. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012;67:71-9. [: Welte 2012]
7. Kohno S, Watanabe A, Aoki N, Niki Y. Clinical evaluation of telithromycin for community-acquired pneumonia - phase III double-blind comparative study of telithromycin versus levofloxacin [Japanese]. Japanese Journal of Chemotherapy 2003;51(Suppl 1):255-78.
8. Mathers Dunbar L, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clinical Therapeutics 2004;26(1):48-62.
9. Oldach D, Clark K, Schranz J, Das A, Craft JC, Scott D, et al. Randomized, double-blind, multicentre phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrobial Agents and Chemotherapy 2013;57(6):2526-34.
10. Udupa A, Gupta P. Antibiotic therapy in pneumonia: a comparative study of oral antibiotics in a rural healthcare centre. International Journal of Pharmacy and Pharmaceutical Sciences 2011;3:156-8.
11. Vacarezza M, Pedrouzo RV, Bartesaghi L, Sicca M, Lerena V, Perdomo J, et al. Community-acquired acute pneumonias in the adult. Controlled therapeutic study. Uruguay [Neumona aguda del adulto adquirida en la comunidad. Ensayo terapéutico controlado. Uruguay]. Archivos de Medicina Interna 2010;XXXII(2-3):31-5.
12. van Rensburg D, Perng R-P, Mitha IH, Bester AJ, Kasumba J, Wu R-G, et al. Efficacy and safety of nemonoxacin versus levofloxacin for community acquired pneumonia. Antimicrobial Agents and Chemotherapy 2010;54(10):4098-106.
13. van Rensburg D, Perng R-P, Mitha IH, Bester AJ, Kasumba J, Wu R-G, et al. Efficacy and safety of nemonoxacin versus levofloxacin for community acquired pneumonia. Antimicrobial Agents and Chemotherapy 2010;54(10):4098-106.
14. Alcacer F, Belda A, Custardoy J, Borras F, Redondo A, Borja J, et al.[Estudio comparativo entre ofloxacino y eritromicina en el tratamiento de la neumonia de la comunidad]. Revista Española de Quimioterapia 1993;6(3):213-8.
15. Arifin NM, Soepandi P, Burhan E, Isbaniah F, Arimah C, Kusumo D, et al. P319 Multicenter, comparative study of levofloxacin high-dose, IV oral sequential therapy for CAP with moxifloxacin in Indonesia. International Journal of Antimicrobial Agents 2013;42(Suppl):S142.
16. Bai N, Sun C, Wang J, Cai Y, Liang B, Zhang L, et al. Ertapenem versus ceftriaxone for the treatment of complicated infections: a meta-analysis of randomized controlled trials. Chinese Medical Journal 2014;127(6):1118-25. [PUBMED: 24622445]
17. Balgos AA, Rodriguez-Gomez G, Nasnas R, Mahasur AA, Margono BP, Tinoco-Favila JC. Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections. International Journal of Clinical Practice 1999;53(5):325-30.
18. Ball P. Efficacy and safety of cefprozil versus other beta-lactam antibiotics in the treatment of lower respiratory tract infections. European Journal of Clinical Microbiology and Infectious Diseases 1994;13(10):851-6.
19. Balmes P, Clerc G, Dupont B, Labram C, Pariente P, Poirier R. Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections. European Journal of Clinical Microbiology and Infectious Diseases 1991;10:437-9.
20. Bantz PM, Grote J, Peters-Haertel W, Stahmann J, Timm J, Kasten R, et al. Low-dose ciprofloxacin in respiratory tract infections: a randomized comparison with doxycycline in general practice. American Journal of Medicine 1987;82(Suppl 4A):208-10.
21. Biermann C, Loken A, Riise R. Comparison of spiramycin and doxycycline in the treatment of lower respiratory infections in general practice. Journal of Antimicrobial Chemotherapy 1988;22(Suppl B):155-8.
22. Blasi F, Tarsia P, Mantero M, Morlacchi LC, Piffer F. Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication. Journal of Therapeutics and Clinical Risk Management 2013;9:55-64.
23. Block SL. Comparative tolerability, safety and efficacy of tablet formulations of twice-daily clarithromycin 250 mg versus once-daily extended-release clarithromycin 500 mg in pediatric and adolescent patients. Clinical Pediatrics 2006;45(7):641-8.
24. Bonvehi P, Weber K, Busman T, Shortridge D, Notario G. Comparison of clarithromycin and amoxicillin/clavulanic acid for community-acquired pneumonia in an era of drug-resistant streptococcus pneumoniae. Clinical Drug Investigation 2003;23(8):491-501.
25. Bothra M, Lodha R, Kabra SK. Tobramycin for the treatment of bacterial pneumonia in children. Expert Opinion on Pharmacotherapy 2012;13(4):565-71.
26. Brittain-Long R, Westin J, Olofsson S, Lindh M, Andersson LM. Access to a polymerase chain reaction assay method targeting 13 respiratory viruses can reduce antibiotics: a randomised, controlled trial. BMC Medicine 2011;9:44.
27. Carbon C, Ariza H, Rabie WJ, Salvarezza CR, Elkharrat D, Rangaraj M, et al. Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mild-to-moderate community-acquired pneumonia. Clinical Microbiology and Infection 1999;5:724-32.
28. Casapao AM, Steed ME, Levine DP, Rybak MJ. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. Expert Opinion on Pharmacotherapy 2012;13(8):1177-86.
29. Chodosh S. Temafloxacin compared with ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients. Chest 1991;100:1497-502.
30. Critchley I, Friedland D, Eckburg P, Jandourek A, Han S, Thye D. Microbiological outcomes of 2 multicenter phase 3 clinical trials of ceftaroline in community-acquired bacterial pneumonia. American Journal of Respiratory and Critical Care Medicine 2010;181:A5481.
31. Daniel R. Oral trovafloxacin compared with amoxicillin (plus optional erythromycin) for the treatment of mild to moderate community-acquired pneumonia. Drugs 1999;58(Suppl 2):320-2.
32. Daniel R. Trovafloxacin vs high dose amoxicillin in the treatment of community-acquired bacterial pneumonia. Drugs 1999;58(Suppl 2):304-5.
33. Dark D. Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections. American Journal of Medicine 1991;91(Suppl 3A):31-5.
34. Dartois N, Cooper CA, Castaing N, Gandjini H, Sarkozy D. Tigecycline versus levofloxacin in hospitalized patients with community-acquired pneumonia: an analysis of risk factors. Open Respiratory Medicine Journal 2013;7:13-20. [PUBMED: 23526572]
35. Dautzenberg B, Scheimberg A, Brambilla C, Camus P, Godard P, Guerin JC. Comparison of two oral antibiotics, roxithromycin and amoxicillin plus clavulanic acid, in lower respiratory tract infections. Diagnostic Microbiology and Infectious Disease 1992;15(Suppl):85-9.
36. Dean NC, Sperry P, Wikler M, Suchyta MS, Hadlock C. Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care. Antimicrobial Agents and Chemotherapy 2006;50(4):1164-9.
37. De Cock L, Poels R. Comparison of spiramycin with erythromycin for lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 1988;22(Suppl B):159-63.
38. Donowitz GR, Brandon ML, Salisbury JP, Harman CP, Tipping DM, Urick AE, et al. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study. Clinical Therapeutics 1997;19(5):936-53.
39. Esposito S, Esposito I, Leone S. Considerations of antibiotic therapy duration in community and hospital-acquired bacterial infections. Journal of Antimicrobial Chemotherapy 2012;67(11):2570-5.
40. File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrobial Agents and Chemotherapy 1997;41(9):1965-72.
41. File TM Jr, Schlemmer B, Garau J, Cupo M, Young C, 049 Clinical Study Group. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. Journal of Antimicrobial Chemotherapy 2001;48(1):67-74.
42. File TM Jr, Lode H, Kurz H, Kozak R, Xie H, Berkowitz E, et al. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced-amoxicillin clavulanate (2, 000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrobial Agents and Chemotherapy 2004;48(9):3323-31.
43. File Jr T, Eckburg P, Low D, Talbot G, llorens L, Friedland HD. Assessment of outcomes at an entry time point may identify a differential effect of macrolide therapy on community-acquired pneumonia due to atypical pathogens. Clinical Microbiology and Infection 2012;18(55):133-4.
44. File Jr TM, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clinical Infectious Diseases 2012;55(Suppl 3):173-80.
45. Fogarty C, Grossman C, Williams J, Haverstock D, Church D for the Community-Acquired Pneumonia Study Group. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infections in Medicine 1999;16:748-63.
46. Fogarty CM, Cyganowski M, Palo WA, Hom RC, Craig WA. A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study. Clinical Therapeutics 2002;24(11):1854-70.
47. Fogarty C, Siami G, Kohler R, File Jr TM, Tennenberg AM, Olson WH, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clinical Infectious Diseases 2004;38(Suppl 1):16-23.
48. Fong IW, Laforge J, Dubois J, Small D, Grossman R, Zakhari R, et al. Clarithromycin versus cefaclor in lower respiratory tract infections. Clinical and Investigative Medicine 1995;18:131-8.
49. Fujita J, Niki Y, Kadota J, Yanagihara K, Kaku M, Watanabe A, et al. Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial. Journal of Infection and Chemotherapy (Official Journal of the Japan Society of Chemotherapy) 2013;19(3):472-9.
50. Ghebremedhin B. Bacterial infections in the elderly patient: focus on sitafloxacin. Clinical Medicine Insights: Therapeutics 2012;4:185-200.
51. Gotfried MH, Dattani D, Riffer E, Devcich KJ, Busman TA, Notario GF, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clinical Therapeutics 2002;24(5):736-51.
52. Gris P. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study. Journal of Antimicrobial Chemotherapy 1996;37(Suppl C):93-101.
53. Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection 2002;30(6):378-86.
54. Higuera F, Hidalgo H, Feris J, Giguere G, Collins JJ. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia. Journal of Antimicrobial Chemotherapy 1996;37:555-64.
55. Hoeffken G, Meyer HP, Winter J, Verhoef L, CAP1 Study Group. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respiratory Medicine 2001;95(7):553-64.
56. Hoepelman AIM, Sips AP, van Helmond JLM, van Barneveld PWC, Neve AJ, et al. A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 1993;31(Suppl E):147-52.
57. Hoepelman IM, Möllers MJ, van Schie MH, Greefhorst APM, Schlösser NJJ, Sinninghe Damsté EJ, et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. International Journal of Antimicrobial Agents 1998;9:141-6.
58. Kammer RB, Ress R. Randomized comparative study of ceftibuten versus cefaclor in the treatment of acute lower respiratory tract infections. Diagnostic Microbiology and Infectious Disease 1991;14:101-5.
59. Kiani R, Coulson L, Johnson D, Hammershaimb L. Comparison of once-daily and twice-daily cefixime regimens with amoxicillin in the treatment of acute lower respiratory tract infections. Current Therapeutic Research, Clinical and Experimental 1990;48(5):841-52.
60. Kinasewitz G, Wood RG. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 1991;10(10):872-7.
61. Kohno S, Yanagihara K, Yamamoto Y, Tokimatsu I, Hiramatsu K, Higa F, et al. Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan. Journal of Infection and Chemotherapy (Official Journal of the Japan Society of Chemotherapy) 2013;19(6):1035-41.
62. Lacny J. A comparison of oral therapy with clindamycin and penicillin G in common gram-positive infections. Current Therapeutic Research 1972;14(1):26-30.
63. Lagler H, Gattringer R, Derler V, Wlazny D, Graninger W, Burgmann H. Intravenous azithromycin - single dose 1.5 g vs. 500 mg once daily for 3 days in patients with community-acquired pneumonia: a prospective and randomized study. Clinical Microbiology and Infection 2012;18(65):137-8.
64. Laurent K. Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 1996;37(Suppl C):115-24.
65. Lee JH, Kim SW, Kim JH, Ryu YJ, Chang JH. High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study. Clinical Drug Investigation 2012;32(9):569-76.
66. Léophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respiratory Medicine 2004;98(8):708-20.
67. Liippo K, Tala E, Puolijoki H, Brückner OJ, Rodrig J, Smits JPH. A comparative study of dirithromycin and erythromycin in bacterial pneumonia. Journal of Infectious Diseases 1994;28:131-9.
68. Little P, Stuart B, Moore M, Coenen S, Butler CC, Godycki-Cwirko M, et al. Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial. Lancet Infectious Diseases 2013;13(2):123-9.
69. Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. European Respiratory Journal 1995;8:1999-2007.
70. Lode H, Aubier M, Portier H, Ortqvist A and the Sparfloxacin Study Group. Sparfloxacin as alternative treatment to standard therapy for community-acquired bacteremic pneumococcal pneumonia. Clinical Microbiology and Infection 1998;4(3):135-43.
71. Lode H, Magyar P, Muir JF, Loos U, Kleutgens K, International Gatifloxacin Study Group. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia. Clinical Microbiology and Infection 2004;10(6):512-20.
72. Lode H, Aronkyto T, Chuchalin AG, Jaaskevi M, Kahnovskii I, Kleutgens K, et al. A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia. Clinical Microbiology and Infection 2004;10(5):403-8.
73. Long W, Deng X, Zhang Y, Lu G, Xie J, Tang J. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 2011;16(5):819-24.
74. López-Véjar CE, Castellanos de la Cruz L, Meraz-Ortega R, Román- Flores A, Geuguer-Chávez L, Pedro-González A, et al.[Eficacia del levofloxacino en el tratamiento de neumonía adquirida en la comunidad]. Medicina Interna de México 2013;29(587):594.
75. MacFarlane JT, Prewitt J, Gard P, Guion A. Comparison of amoxycillin and clarithromycin as initial treatment of community-acquired lower respiratory tract infections. British Journal of General Practice 1996;46(407):357-60.
76. Matzneller P, Krasniqi S, Kinzig M, Sörgel F, Hüttner S, Lackner E, et al. Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrobial Agents and Chemotherapy 2013;57(4):1736-42.
77. Montassier E, Goffinet N, Potel G, Batard E. How to reduce antibiotic consumption for community-acquired pneumonia. Medicines et Maladies Infectieuses 2013;43(2):52-9.
78. Moola S, Hagberg L, Churchyard GA, Dylewski JS, Sedani S, Staley H. A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. Chest 1999;116(4):974-83.
79. Müller O, Wettich K. Comparison of loracarbef (LY 163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia. Infection 1992;20(3):176-82.
80. Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor. Antimicrobial Agents and Chemotherapy 2013;57(5):2005-9.
81. The Nordic Atypical Pneumonia Study Group. Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Journal of Antimicrobial Chemotherapy 1997;39:499-508.
82. Navarta AC, Bocklet ML, Anzorena A, Cuello H, Carena JA. Not available [Eficacia clínica de los macrólidos como parte del tratamiento empírico en neumonía de la comunidad que se interna]. Revista Americana de Medicina Respiratoria 2010;3:97-104.
83. Neu HC, Chick TW. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest 1993;104:1393-9.
84. Nussenblatt V, Avdic E, Cosgrove S. What is the role of antimicrobial stewardship in improving outcomes of patients with CAP. Infectious Disease Clinics of North America 2013;27(1):211-28.
85. O'Doherty B, Dutchman DA, Pettit R, Maroli A. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. Journal of Antimicrobial Chemotherapy 1997;40(Suppl A):73-81.
86. O'Doherty B, Muller O and the Azithromycin Study Group. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 1998;17:828-33.
87. Örtqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C, et al. Oral empiric treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest 1996;110:1499-506.
88. Pavie J, de la Prida JM, Diaz A, Saldias F. Assessment of the management of community-acquired pneumonia in adult outpatients [Manejo ambulatorio de la neumonía comunitaria del adulto en las unidades de emergencia. Servicio de Salud Vina del Mar-Quillota de la V Región]. Revista Médica de Chile 2005;133:1322-30.
89. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J, CAP5 Moxifloxacin Study Group. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119(1):185-95.
90. Peugeot RL, Lipsky BA, Hooton TM, Pecoraro RE. Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin. Drugs in Experimental and Clinical Research 1991;17(5):253-7.
91. Polverino E, Cilloniz C, Dambrava P, Gabarrus A, Ferrer M, Agusti C, et al. Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome. Respirology 2013;18(2):263-71.
92. Pullman J, Champlin J, Vrooman PS Jr. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Internation Journal of Clinical Practice 2003;57(5):377-84.
93. Rahav G, Fidel J, Gibor Y, Shapiro M. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. International Journal of Antimicrobial Agents 2004;24(2):181-4.
94. Ramirez J, Unowsky J, Talbot GH, Zhang H, Townsend L. Sparfloxacin vs clarithromycin in the treatment of community acquired pneumonia. Clinical Therapeutics 1999;21(1):103-17.
95. Rank DR, Friedland HD, Eckburg PB, Smith A, Thye D. Integrated safety summary of ceftaroline fosamil (cpt): safety in patients overall and for patients with community-acquired pneumonia (cap). American Journal of Respiratory and Critical Care Medicine 2011;183:A3357.
96. Rayman J, Krchnavý M, Balciar P, Duchon J, Fortuník J, Faith L, et al. Ofloxacin once daily versus twice daily in community-acquired pneumonia and acute exacerbation of chronic bronchitis. Chemotherapy 1996;42:227-30.
97. Saito A, Watanabe A, Aoki N, Niki Y, Kohno S, Kaku M, et al. Phase III double-blind comparative study of sitafloxacin versus tosufloxacin in patients with community-acquired pneumonia. Japanese Journal of Chemotherapy 2008;56(Suppl 1):49-62.
98. Salvarezza CR, Mingrone H, Fachinelli H, Kijanczuk S. Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia. Journal of Antimicrobial Chemotherapy 1998;41(Suppl B):75-80.
99. Schleupner CJ, Anthony WC, Tan J, File TM, Lifland P, Craig W, et al. Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections. Archives of Internal Medicine 1988;148:343-8.
100. Seki M, Higashiyama Y, Imamura Y, Nakamura S, Kurihara S, Izumikawa K, et al. A clinical comparative study of piperacillin and sulbactam/ampicillin in patients with community-acquired bacterial pneumonia. Internal Medicine 2009;48(1):49-55.
101. Shorr AF, Kollef M, Eckburg PB, Llorens L, Friedland HD. Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials. Diagnostic Microbiology and Infectious Disease 2013;75(3):298-303.
102. Siquier B, Sánchez-Alvarez J, García-Mendez E, Sabriá M, Santos J, Pallarés R, et al. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 2006;57(3):536-45.
103. Skalsky K, Yahav D, Lador A, Eliakim-Raz N, Leibovici L, Paul M. Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials. Clinical Microbiology and Infection 2013;19(4):370-8.
104. Smith KJ, Wateska A, Nowalk MP, Raymund M, Lee BY, Zimmerman RK, et al. Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia. Journal of General Internal Medicine 2013;28(9):1157-64.
105. Snyman JR, Schoeman HS, Grobusch MP, Henning M, Rabie W, Hira M, et al. Generic versus non-generic formulation of extended-release clarithromycin in patients with community-acquired respiratory tract infections: a prospective, randomized, comparative, investigator-blind, multicentre study. Clinical Drug Investigation 2009;29(4):265-74.
106. Sokol WN Jr, Sullivan JG, Acampora MD, Busman TA, Notario GF. A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia. Clinical Therapeutics 2002;24(4):605-15.
107. Sopena N, Martínez-Vázquez C, Rodríguez-Suárez JR, Segura F, Valencia A, Sabrià M. Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults. Journal of Chemotherapy 2004;16(1):102-3.
108. Stille W, Sab R, Klinge R, Loos U, AlthoffP-H, Kullmann K-H. Ceftriaxon i. v./efetametpivoxil versus efuroxim i. v./efuroximatxetil. Chemotherapie Journal 2000;9(2):87-92.
109. Sun H, Maitetta R, Machineni J, Praestgaard J, Kuemell A, Stein D, et al. A single-dose study to evaluate the pharmacokinetics, safety and tolerability of multiple formulations of PTK0796 in healthy subjects. Clinical Microbiology and Infection 2012;18(94):374-5.
110. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. Journal of Antimicrobial Chemotherapy 2004;54(2):515-23.
111. Tilyard MW, Dovey SM. A randomized double-blind controlled trial of roxithromycin and cefaclor in the treatment of acute lower respiratory tract infections in general practice. Diagnostic Microbiology and Infectious Disease 1992;15:97-101.
112. Torres A, Muir JF, Corris P, Kubin R, Duprat-Lomon I, Sagnier PP, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. European Respiratory Journal 2003;21(1):135-43.
113. Trémolières F, de Kock F, Pluck N, Daniel R. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 1998;17(6):447-53.
114. Trémolières F, Mayaud C, Mouton Y, Weber P, Dellatolas F, Caulin E. Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults [Essai comparatif de l'efficacité et de la tolérance de la pristinamycine vs amoxicilline dans le traitement des pneumonies aigues communautaires de l'adulte]. Pathologie-Biologie 2005;53(8-9):503-10.
115. van Zyl L, le Roux JG, LaFata JA, Volk RS, Palo WA, Flamm R, et al. Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study. Clinical Therapeutics 2002;24(11):1840-53.
116. Viasusa D, Garcia-Vidala C, Carratala J. Advances in antibiotic therapy for community acquired pneumonia. Current Opinion in Pulmonary Medicine 2013;19(3):209-15.
117. Worrall G, Kettle A, Graham W, Hutchinson J. Postdated versus usual delayed antibiotic prescriptions in primary care: reduction in antibiotic use for acute respiratory infections. Canadian Family Physician 2010;56(10):1032-6.
118. Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. American Journal of Respiratory and Critical Care Medicine 2011;183(11):1561-8.
119. Yamamoto Y, Izumikawa K, Morinaga Y, Nakamura S, Kurihara S, Imamura Y, et al. Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan. Journal of Infection and Chemotherapy (Official Journal of the Japan Society of Chemotherapy) 2013;19(2):291-8.
120. Yuan X, Liang B-B, Wang R, Liu Y-N, Sun C-G, Cai Y, et al. Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials. Journal of Chemotherapy 2012;24(5):257-67.
121. Zhang L, Huang J, Xu T, Lin Y. Procalcitonin-guided algorithms of antibiotic therapy in community-acquired lower respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. Chinese Journal of Tuberculosis and Respiratory Diseases 2010;35(4):275-82.
122. Zuck P, Rio Y, Ichou F. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. Journal of Antimicrobial Chemotherapy 1990;26(Suppl E):71-7.
123. Grupo de trabajo de la Asociación Latinoamericana del Tórax (ALAT). Latin American Thoracic Association (ALAT) recommendations on community acquired pneumonia [Recomendaciones ALAT sobre la neumonía adquirida en la comunidad]. Archivos de Bronconeumología 2001;37:340-8.
124. Grupo de trabajo de la Asociación Latinoamericana del Tórax (ALAT). Update to the Latin American Thoracic Association (ALAT) recommendations on community acquired pneumonia. Archivos de Bronconeumología 2004;40(8):364-74.
125. Armitage P, Berry G. Statistical Methods in Medical Research. 3rd Edition. Oxford: Blackwell Scientific Publications, 1994.
126. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. American Journal of Critical Care 2001;163:1730-54.
127. Macfarlane JT, Boldy D. 2004 update of BTS pneumonia guidelines: what's new?. Thorax 2004;59(5):364-6. [: Macfarlane 2004;: www.brit-thoracic.org.uk/guidelines]
128. Lim WS, Baudoui SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64(Suppl 3):iii1-iii55.
129. Carratalà J, Fernández-Sabé N, Ortega L, Castellsagué X, Rosón B, Dorca J, et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Annals of Internal Medicine 2005;142(3):165-72.
130. Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clinical Infectious Diseases 2000;31:383-421.
131. Foy HM, Cooney MK, Allan I, Kenny GE. Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975. JAMA 1979;241:253-8.
132. Hedlund J, Strålin K, Ortqvist A, Holmberg H, Community-Acquired Pneumonia Working Group of the Swedish Society of Infectious Diseases. Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults. Scandinavian Journal of Infectious Diseases 2005;37(11-2):791-805.
133. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
134. Höffken G, Lorenz J, Kern W, Welte T, Bauer T, DalhoffK, et al. Guidelines of the Paul-Ehrlich-Society of Chemotherapy, the German Respiratory Diseases Society, the German Infectious Diseases Society and of the Competence Network CAPNETZ for the Management of Lower Respiratory Tract Infections and Community Acquired Pneumonia: Summary of the Update 2009. Pneumologie 2010;64:149-54. [: German guidelines 2009]
135. Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clinical Infectious Diseases 2000;31:347-82.
136. Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clinical Infectious Diseases 2003;37:1405-33.
137. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases 2007;44(Suppl 2):27-72.
138. Jokinen C, Heiskanen L, Juvonen H, Kallinen S, Karkola K, Korppi M, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. American Journal of Epidemiology 1993;137:977-88.
139. Committee for The Japanese Respiratory Society guidelines for the management of respiratory infections. Guidelines for the management of community acquired pneumonia in adults, revised edition. Respirology 2006;11(Suppl 3):79-133.
140. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011.
141. Loeb M. Community-acquired pneumonia. Clinical Evidence. Vol. 8, London: BMJ Publishing Group, 2002.
142. Macfarlane JT, Miller AC, Roderick Smith WH, Morris AH, Rose DH. Comparative radiographic features of community-acquired legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia and psittacosis. Thorax 1984;39:28-33.
143. Maimon N, Nopmaneejumruslers C, Marras TK. Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis. European Respiratory Journal 2008;31(5):1068-76.
144. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases 2007;44(Suppl 2):27-72.
145. Memish ZA, Arabi YM, Ahmed QA, Shibl AM, Niederman MS, GCC CAP Working Group. Executive summary of the Gulf Cooperation Council practice guidelines for the management of community-acquired pneumonia. Journal of Chemotherapy 2007;19(Suppl 1):7-11. [: Memish 2007]
146. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
147. Robenshtok E, Shefet D, Gafter-Gvili A, Paul M, Vidal L, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004418.pub3]
148. Working Group of the South African Thoracic Society. Management of community-acquired pneumonia in adults. South African Medical Journal 2007;97(12 Pt 2):1296-306.
149. Spindler C, Strålin K, Eriksson L, Hjerdt-Goscinski G, Holmberg H, Lidman C, et al. Swedish guidelines on the management of community-acquired pneumonia in immunocompetent adults--Swedish Society of Infectious Diseases 2012. Scandinavian Journal of Infectious Diseases 2012;44(12):885-902.
150. Strålin K, Goscinski G, Hedlund J, Lidman C, Spindler C, Ortqvist A, et al. Management of adult patients with community-acquired pneumonia. Evidence-based guidelines from the Swedish Infectious Diseases Association [Handläggning av samhälls-förvärvad pneumoni hos vuxna. Evidensbaserade riktlinjer från Svenska infektionsläkarföreningen. (Abridged version of the 2007 update; http://www.infektion.net/klinik/lunga/pneumoni/Vardprogram_Pneumoni_slutvers_2007.pdf (in Swedish) (accessed 23 March 2009)]. Lakartidningen 2008;105(38):2582-7.
151. Torres A, Serra-Batlles J, Ferrer A, Jiménez P, Celis R, Cobo E, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. American Review of Respiratory Disease 1991;144:312-8.
152. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012;67:71-9.
153. Wiersinga WJ, Bonten MJ, Boersma WG, Jonkers RE, Aleva RM, Kullberg BJ, et al. Dutch guidelines on the management of community-acquired pneumonia in adults. SWAB/NVALT Guidelines Community-acquired Pneumonia 2011.
154. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987;i:671-4.
155. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Guidelines for the management of adult lower respiratory tract infections--full version. Clinical Microbiology and Infection 2011;17(Suppl 6):E1-59.
156. Bjerre LM, Verheij TJ, Kochen MM. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD002109.pub2]
157. Bjerre LM, Verheij TJ, Kochen MM. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD002109.pub3]